DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for brachial plexus neuropathy — screening already-approved drugs against its 23-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrachial plexus neuropathy maps to a 23-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brachial plexus neuropathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 6D (PDE6D) — PDE6D is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4JV8 · 1.45 Å · ligand (6R)-6-(pyridin-2-yl)-5,6-dihydrobenzimidazo[1,2-c]quinazoline (1M1). Experimental structure, not a prediction.
What the evidence adds up to
In 1972 a natural history study of 99 patients with brachial plexus neuropathy reported that the overall prognosis was excellent despite the severity and extent of the lesion. Improvement could begin in one to two months, but complete functional recovery might not be achieved for up to three years or longer. No difference in clinical aspects or recovery rates was found between patients who had antecedent immunisations and those who did not. A 2000 retrospective study of 16 patients with a mean follow-up of eight years found a less favourable long-term outcome: nine patients complained of persistent pain and muscle weakness, four had continuing problems with activities of daily living, eleven had trouble with housekeeping activities, and eight had to change their occupation.
A 2020 retrospective study of 30 patients with total brachial plexus injury and neuropathic pain reported that the average pain score on a visual analogue scale was 7.13 preoperatively and 5.40 postoperatively after surgical repair. Patients were divided into a pain relief group and a pain aggravation group. Older age, machine traction injury, and nerve transplantation appeared to be associated with pain aggravation. Paroxysmal pain was aggravated after surgical repairs, while paresthesia or dysesthesia improved. Spontaneous permanent pain did not show any significant change. Pain in the C5 and C6 dermatomes was relieved after surgery.
No drug treatment is mentioned in any of these abstracts. The 1972 study explicitly states that the cause remains unknown. The 2000 study suggests that persistent symptoms and occupational change are common in the long term, contradicting the earlier claim of excellent prognosis. The 2020 study shows that surgical repair can reduce some types of neuropathic pain but may worsen others, and that certain patient characteristics predict worse pain outcomes.
What is still missing is any randomised controlled trial of a pharmacological intervention for brachial plexus neuropathy, any prospective study that stratifies patients by aetiology or lesion pattern, and any funding for such work. Without these, the natural history and surgical outcomes remain the only evidence, and they are contradictory and incomplete.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Neurology · 1972 · 531 citations
Natural History of Brachial Plexus Neuropathy
AbstractA clinical analysis of 99 patients with brachial plexus neuropathy (BPN) and the outcome of 84 of these patients are presented. The disease may involve the upper, the lower, or the entire plexus; the involvement may be complete or incomplete, and it may often be bilateral. Although the etiologic factor or factors remain unknown, our studies support the contention that this form of neuropathy is a clinical entity with, in most cases, a fairly typical pattern of symptoms and signs. The overall prognosis is excellent despite the severity and extent of the lesion. There is no apparent difference in the clinical aspects and recovery rates between patients who had antecedent immunizations and those who did not. While improvement may begin in one to two months, complete functional recovery may not be achieved for up to three years or longer in some cases.
Bilateral diaphragmatic weakness: a late complication of radiotherapy
AbstractBrachial plexus neuropathy is an unfortunate complication that sometimes follows radiotherapy to the axillary and supraclavicular regions. A patient is described who, 30 years after radiotherapy for Hodgkin's disease and more than 10 years after the development of radiation-induced bilateral brachial plexus neuropathy, presented with bilateral diaphragmatic weakness secondary to bilateral phrenic nerve weakness. Previous radiotherapy was the most probable cause of the condition.
Journal of Hand Surgery (European Volume) · 2000 · 21 citations
BRACHIAL PLEXUS NEUROPATHY A long-term outcome study
AbstractThis retrospective study assessed the long-term outcome of brachial plexus neuropathy in 16 patients. The mean follow up was 8 years. Nine patients complained of persistent pain and muscle weakness, four had continuing problems with various activities of daily living and 11 had trouble with some housekeeping activities. Furthermore, eight of the patients had to change their occupation.
Clinical Neurology and Neurosurgery · 2020 · 9 citations · open access
Comparison of neuropathic pain characteristics associated with total brachial plexus injury before and after surgical repair: A retrospective study
AbstractOBJECTIVES: The goal of this study was to compare clinical characteristics of neuropathic pain associated with total brachial plexus injury before and after surgeries and to correlate possible contributing factors concerning to the pain prognosis. PATIENTS AND METHODS: Thirty patients with both total brachial plexus injury and neuropathic pain were included. Neuropathic pain was evaluated in terms of pain intensities, symptoms and regions. Pain intensities were evaluated by a visual analogue scale. The Neuropathic Pain Symptoms Inventory questionnaire and body maps were used to compare the pain symptoms and regions. Demographic data, injury and repair information were evaluated to analyze the possible factors influencing the prognosis. RESULTS: The average pain score of all participants was 7.13 ± 2.46 preoperatively and 5.40 ± 2.08 postoperatively. All patients were divided into Pain Relief Group and Pain Aggravation Group. Older age (p = 0.042), machine traction injury (p = 0.019)and nerve transplantation(p = 0.015) seemed to be related with pain aggravation. Paroxysmal pain was aggravated after surgical repairs (p = 0.041), while paresthesia/dysesthesia improved after surgery (p = 0.003). The permanent component of the pain (spontaneous pain) did not show any significant change (p = 0.584). Pain in C5 (p < 0.001) and C6 (p = 0.031) dermatomes got relieved after surgery. CONCLUSION: This study revealed the neuropathic pain of most patients with total brachial plexus injury was alleviated after neurosurgery, and the pain prognosis of different symptoms and regions varied after the nerve repair.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
